We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Service Launched for Measuring Abeta Plaques in AD Patients

By LabMedica International staff writers
Posted on 20 Jul 2009
A diagnostic test quantitatively measures amyloid in the brain of Alzheimer disease (AD) patients months earlier than the current microscopic approach. A company focused on treatments for brain-wasting diseases has launched a diagnostic service using this test.

Aggregated misfolded proteins are a common element of many brain-wasting diseases. The ability to identify AMPs and understand their structure and mechanism of folding are the first steps to developing new treatments for these devastating diseases.

Image: Colored light micrograph of brain tissue from an Alzheimer’s disease patient, showing a large plaque (blue) containing the abnormal protein amyloid (Photo courtesy of Simon Fraser / SPL).
Image: Colored light micrograph of brain tissue from an Alzheimer’s disease patient, showing a large plaque (blue) containing the abnormal protein amyloid (Photo courtesy of Simon Fraser / SPL).

The hallmark of Alzheimer's disease (AD) is the aggregation and accumulation of beta-amyloid as plaques in the brain. Amorfix Life Sciences (Toronto, Canada) presented a paper on the new beta amyloid (Abeta) assay at the International Conference on Alzheimer's Disease (ICAD; 2009) on July 15, 2009 in Vienna (Austria), thereby launching the company's AD diagnostic service.

The Abeta assay is significantly more sensitive than current detection methods and can be used in high-throughput applications designed to study the inhibition of amyloid formation. Dr. George Adams, CEO of Amorfix, said, "There are over 300 companies and thousands of researchers studying AD and seeking new treatments, who could benefit from this sensitive and specific test for beta-amyloid."

The aggregated-amyloid assay can detect beta-amyloid (Abeta) in standard animal models of AD several months before conventional microscopic procedures, and can therefore accelerate the preclinical screening of new drugs for the disease.

Amorfix Life Sciences is a theranostics company, which develops therapeutic products and diagnostic devices targeting brain-wasting diseases including amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, and variant Creutzfeldt-Jakob disease (vCJD).

"We are very pleased with the initial response from the pharmaceutical and academic communities to our amyloid testing service," commented Dr. Adams.

Amorfix's lead programs are a diagnostic blood screening test for vCJD and a therapy for ALS.

Related Links:

Amorfix Life Sciences



New
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Automated Blood Typing System
IH-500 NEXT
New
Vibrio Cholerae O1/O139 Rapid Test
StrongStep Vibrio Cholerae O1/O139 Antigen Combo Rapid Test
New
17 Beta-Estradiol Assay
17 Beta-Estradiol Assay

Latest Industry News

Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

Microbiologics Acquires Diagnostic Quality Controls Manufacturer SensID

Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests